AGROSPHERES ANNOUNCES NOVEL MODALITIES PARTNERSHIP WITH BAYER

AgroSpheres’ AgriCell technology will help deliver the next generation of high-performing, environmentally safe crop protection

CHARLOTTESVILLE, VA – AgroSpheres, INC., a leader in developing the next generation of environmentally friendly crop protection products, today announced a multi-year collaboration with Bayer to create novel modalities of biologicals for use as crop protection products.

“Teaming up with a leading global partner like Bayer helps us execute a mission we are both passionate about – transforming agriculture with better and more sustainable products for growers,” said Ameer Shakeel, Founder and CTO of AgroSpheres. “This collaboration also brings us one step closer to establishing AgroSpheres as a next-generation biosciences company.”

AgroSpheres’ patented AgriCell manufacturing technology enables the production of encapsulated biomolecules with enhanced stability, field persistence and targeted delivery.

“AgroSpheres’ novel AgriCell systems are innovative technologies that will help us to explore new sustainable crop protection products,” said Rachel Rama, Head of Small Molecules for Bayer. “AgroSpheres’ cutting-edge scientific team will help us as we continue to improve innovative product offerings for our grower customers.”

Biomolecules such as peptides and nucleic acids have demonstrated great promise in the lab but have generally struggled to yield consistent results for commercial biological development. The AgriCell technology fills the missing link in delivering reliable field performance and opening new markets for high-performance biopesticides. Used with novel modalities, AgriCell technology will help deliver biopesticides that:

Outperform traditional biologicals	Are non-toxic to humans and animals
Are durable in the environment	Target specific pests
Help manage resistance

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline. …

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems …

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and …

News